Insulet Corp is a healthcare company specializing in the development and manufacturing of innovative insulin delivery systems for individuals with diabetes
The company is best known for its Omnipod Insulin Management System, a tubeless, waterproof device that allows users to deliver insulin discreetly and conveniently without the need for traditional syringes or infusion sets. Insulet is committed to enhancing the quality of life for diabetes patients by providing advanced technology solutions that simplify insulin management, improve glycemic control, and promote independence in self-care. Through ongoing research and development, Insulet aims to lead the way in diabetes management innovation.
Insulet Corporation (NASDAQPODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries—Italy, Denmark, Finland, Norway, and Sweden.
Insulet Corporation (NASDAQPODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
Insulet Corporation (NASDAQPODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. (“EOFlow") in federal court.
Insulet Corporation (NASDAQPODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S.
Insulet Corporation (NASDAQPODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time):
The S&P 500 index surged past the 6,000-point milestone, setting fresh record highs, and small-cap stocks are poised for their best weekly performance since April 2024 as investor optimism surrounding the “Trump trade” continued to fuel a strong risk-on sentiment by the end of a wild week in the market.
Insulet Corporation (NASDAQPODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended September 30, 2024.
